All In Biotech

Drug Trial Radar · NCT06505928

A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

A Parallel-group, Randomized, Open-label Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D.

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Dec 11, 2024

Primary completion

May 1, 2026

Study completion Jul 9, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into three groups at a 1:1:1 ratio. The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). Primary endpoint evaluation will be performed after the subjects complete the 48-week treatment.

Conditions

  • Hepatitis D

Interventions

  • hepalatideDrug

    hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. compound responseTime frame: Week 48

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National cancer canter of Monglia

    Ulaanbaatar, Mongolia

  • National Center for Communicable Diseases

    Ulaanbaatar, Mongolia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.